Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008802663> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2008802663 endingPage "241" @default.
- W2008802663 startingPage "234" @default.
- W2008802663 abstract "Efficacy and safety of intermittent intravenous calcitriol therapy were studied in 8 chronic hemodialysis patients with marked hyperparathyroidism refractory to oral therapy with calcium salts and daily vitamin D. They were followed for 20 weeks (32 weeks for 2 patients). At the start of the study, serum calcium was < 2.65 mmol/l and phosphate levels were controlled with calcium-based binders only. The phosphate content of the prescribed diet (< 1 g/day) remained unchanged during the study, and a low-calcium dialysate was used (1.38 mmol/l). The initial postdialysis calcitriol dose was 1 microgram and was increased to 2 micrograms in 6 patients. Intravenous calcitriol effectively improved hyperparathyroidism in 7 patients, with a significant decrease of the intact parathyroid hormone level from 650 +/- 433 to 195 +/- 208 pg/ml (p < 0.05). Hypercalcemia > 2.7 mmol/l occurring in 3 patients was observed in only 11% of the weekly laboratory controls and always resolved rapidly. In contrast, hyperphosphatemia > or = 2.0 mmol/l was observed in 7 patients and in 40% of the weekly laboratory controls. In 15% of the cases the phosphate values even exceeded 2.4 mmol/l. The phosphate binder therapy had to be intensified accordingly, not only by increasing the dose of calcium-based binders, but also by introducing aluminum salts in 6 patients. In summary, our data show that intravenously administered calcitriol is effective in the treatment of severe hyperparathyroidism in most hemodialysis patients resistant to oral therapy. However, its usefulness seems to be limited by frequency and severity of hyperphosphatemia, frequently necessitating additional prescription of aluminum-based binders. These undesirable secondary events may thus limit the long-term utility of intravenously administered calcitriol." @default.
- W2008802663 created "2016-06-24" @default.
- W2008802663 creator A5036632764 @default.
- W2008802663 creator A5045780962 @default.
- W2008802663 creator A5055253820 @default.
- W2008802663 creator A5078768362 @default.
- W2008802663 date "1996-01-01" @default.
- W2008802663 modified "2023-09-27" @default.
- W2008802663 title "High Frequency of Marked Hyperphosphatemia during Intravenous Calcitriol Therapy in Hemodialysis Patients with Refractory Hyperparathyroidism" @default.
- W2008802663 doi "https://doi.org/10.1159/000170266" @default.
- W2008802663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8738537" @default.
- W2008802663 hasPublicationYear "1996" @default.
- W2008802663 type Work @default.
- W2008802663 sameAs 2008802663 @default.
- W2008802663 citedByCount "4" @default.
- W2008802663 countsByYear W20088026632013 @default.
- W2008802663 crossrefType "journal-article" @default.
- W2008802663 hasAuthorship W2008802663A5036632764 @default.
- W2008802663 hasAuthorship W2008802663A5045780962 @default.
- W2008802663 hasAuthorship W2008802663A5055253820 @default.
- W2008802663 hasAuthorship W2008802663A5078768362 @default.
- W2008802663 hasConcept C121332964 @default.
- W2008802663 hasConcept C126322002 @default.
- W2008802663 hasConcept C126894567 @default.
- W2008802663 hasConcept C134018914 @default.
- W2008802663 hasConcept C142424586 @default.
- W2008802663 hasConcept C2775945674 @default.
- W2008802663 hasConcept C2776036575 @default.
- W2008802663 hasConcept C2776079296 @default.
- W2008802663 hasConcept C2777645128 @default.
- W2008802663 hasConcept C2778063415 @default.
- W2008802663 hasConcept C2778838027 @default.
- W2008802663 hasConcept C2781208988 @default.
- W2008802663 hasConcept C519063684 @default.
- W2008802663 hasConcept C71924100 @default.
- W2008802663 hasConcept C87355193 @default.
- W2008802663 hasConcept C90924648 @default.
- W2008802663 hasConceptScore W2008802663C121332964 @default.
- W2008802663 hasConceptScore W2008802663C126322002 @default.
- W2008802663 hasConceptScore W2008802663C126894567 @default.
- W2008802663 hasConceptScore W2008802663C134018914 @default.
- W2008802663 hasConceptScore W2008802663C142424586 @default.
- W2008802663 hasConceptScore W2008802663C2775945674 @default.
- W2008802663 hasConceptScore W2008802663C2776036575 @default.
- W2008802663 hasConceptScore W2008802663C2776079296 @default.
- W2008802663 hasConceptScore W2008802663C2777645128 @default.
- W2008802663 hasConceptScore W2008802663C2778063415 @default.
- W2008802663 hasConceptScore W2008802663C2778838027 @default.
- W2008802663 hasConceptScore W2008802663C2781208988 @default.
- W2008802663 hasConceptScore W2008802663C519063684 @default.
- W2008802663 hasConceptScore W2008802663C71924100 @default.
- W2008802663 hasConceptScore W2008802663C87355193 @default.
- W2008802663 hasConceptScore W2008802663C90924648 @default.
- W2008802663 hasIssue "3" @default.
- W2008802663 hasLocation W20088026631 @default.
- W2008802663 hasLocation W20088026632 @default.
- W2008802663 hasOpenAccess W2008802663 @default.
- W2008802663 hasPrimaryLocation W20088026631 @default.
- W2008802663 hasRelatedWork W1977449477 @default.
- W2008802663 hasRelatedWork W1982480856 @default.
- W2008802663 hasRelatedWork W2005957842 @default.
- W2008802663 hasRelatedWork W2008802663 @default.
- W2008802663 hasRelatedWork W2013152947 @default.
- W2008802663 hasRelatedWork W2072929044 @default.
- W2008802663 hasRelatedWork W2265519523 @default.
- W2008802663 hasRelatedWork W2410697176 @default.
- W2008802663 hasRelatedWork W3030318021 @default.
- W2008802663 hasRelatedWork W3178851656 @default.
- W2008802663 hasVolume "14" @default.
- W2008802663 isParatext "false" @default.
- W2008802663 isRetracted "false" @default.
- W2008802663 magId "2008802663" @default.
- W2008802663 workType "article" @default.